Bridge Occlusion Balloon Catheter Model 590-001 by Spectranetics: Class I Recall - Clinical Issue
Audience: Risk Manager, Emergency Medicine, Cardiology
[Posted 09/25/2017]
ISSUE: Spectranetics is recalling its Bridge Occlusion Balloon Catheter due to the possibility of a blocked guidewire lumen in some device units. If a device with a blocked guidewire lumen were to be used during the procedure, the device would not be positioned correctly and hemorrhage would not be controlled. This would delay life-saving treatment, which may result in immediate and serious adverse health consequences, including death.
- Lot Numbers: FMN17B13A, FMN17C08A, FMN17C28A, FMN17D07A, FMN17D12A, FMN17D19A, FMN17D27A, FMN17E02A, FMN17E23A, FMN17E31A, FMN17E31B, FMN17F06A, FMN17F20A, FMN17F21A, FMN17G12A, FMN17G18A, FMN17H03A, FMN17H03A, FMN17H03A, FMN17H10A, FMN17H29A
- Manufacturing Dates: February 13, 2017 to July 18, 2017
- Distribution Dates: February 24, 2017 to July 31, 2017
- Devices Recalled in the U.S.: 1,900+
BACKGROUND: Spectranetics’ Bridge Occlusion Balloon Catheter is a device intended to temporarily block the superior vena cava (SVC) when emergency control of hemorrhage is required. The Bridge Occlusion Balloon catheter is constructed of a compliant balloon mounted on a dual lumen shaft. The guidewire lumen is used to pass the catheter over a guide wire.
RECOMMENDATION: On August 7, 2017, Spectranetics sent affected customers an “Urgent Medical Device Recall” notice informing them of the device’s risks. The notice directed physicians to confirm that the guidewire lumen is open and unblocked prior to start of the procedure, and to have back up units on hand should they be needed during the procedure.
Spectranetics also sent affected customers an updated notice on August 21, 2017 to notify them that all bridge devices have the potential for guidewire blockage. The updated notice recommended that physicians:
- Place a guide wire through the venous access site and across the length of the SVC prior to the start of the procedure.
- Consider removing the Bridge device from its packaging and placing the catheter over the guidewire prior to the start of the procedure to ensure a patent lumen.
- If the guidewire lumen is obstructed, discard that device and test another until a working device has been identified. Return defective devices to Spectranetics.
- Be aware that all Bridge inventory will continue to have the potential for a guidewire lumen blockage until Spectranetics has implemented a permanent solution.
- Bring extra Bridge inventory into the procedure so that there is a back-up device on hand, should it be determined that the existing unit has a blocked guidewire lumen.
- Always follow appropriate complication prevention and management protocols as they relate to patient preparation and surgical back up for lead extraction procedures.
- Complete and return to Spectranetics the “Acknowledgement and Receipt Form” that accompanied the Urgent Medical Device Recall notice.
- A Spectranetics Sales Representative will be in contact to facilitate the return and replacement of any remaining inventory once new inventory with an implemented fix is available.
On September 7, 2017, Spectranetics sent affected customers an additional notification informing them that follow-up distribution of the device is limited to a 30-day period.
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
- Complete and submit the report Online: www.accessdata.fda.gov/scripts/medwatch/index.cfm
- Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
[09/25/2017 - Recall Notice - FDA]
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.